Skip to content
Navigate to homepage - Cerba Research

Viroclinics-DDL is now Cerba Research

We are transforming clinical research to deliver the promise of precision and predictive medicine to help people live healthier lives.

We’re proud and excited that Viroclinics-DDL, the fast-growing global specialist in virology and immunology, is now Cerba Research. Coming together has expanded and transformed our diagnostic solutions for clinical trials to give you even greater access to exceptional scientific and technical teams in multiple treatment areas for drug and vaccine development. Our joint vision is to transform research and advance health for you, your patients, and scientific communities across the world.

New and improved benefits for you and your teams

Enhanced capabilities

By coming together with Viroclinics-DDL, the Cerba Group has extended our services to offer you preclinical research, clinical trial diagnostics, assay development, and virology clinical trial logistic services. Our enhanced capabilities give you access to in-house laboratory testing to support the development of vaccines, antibodies, and antiviral compounds targeting viral infectious diseases.

Integrated solutions

Together we provide clinical trial central and speciality laboratory services to give you a comprehensive portfolio of solutions and capabilities at every stage of clinical trials, from assay development in multiple therapeutic areas to the latest technology available in flow cytometry, immunohistochemistry, Next Generation Sequencing, and immunoassays.

Deepening therapeutic insight

As well as our unparalleled scientific expertise, you can draw on our fast-expanding portfolio of therapeutic areas, including Oncology and Immuno-Oncology, Metabolic Diseases, Virology and other Infectious Diseases, Inflammatory and Autoimmune Diseases, Neurology and Rare Diseases.

Industry-leading service

Our portfolio of scientific and technical expertise combined with our global capabilities, vast databases of patient data and samples, and best-in-class logistics removes the uncertainty from sample management, reduce risks, and enables the accuracy and acceleration of your drug and vaccine development projects from start to finish.

New highlights for your team

• Early stage and preclinical testing services, including in-house developed customized animal models.
• Access to biomedical and genetic data from over 45 million patients per year from across Europe, Africa, and North America.
Capability to sequence 1000+ whole human genomes per week.
• Unique access to Africa’s growing population including diverse samples for non-clinical research.
• A gateway for customers to conduct studies in China with local capabilities within an integrated global solution.
• Access to exceptional scientific and technical teams in multiple treatment areas for drug and vaccine development.
• A cutting-edge specialist laboratory network of over 1000 labs including in-house BSL2 and BSL3 labs in Europe, the Americas, Africa, Asia and Australia.
Largest global PBMC network
Extended virus biobank services
• Access to specialty techniques including flow cytometry and anatomical pathology solutions.
• Molecular diagnostics expertise, supporting immuno-oncology, cell & gene therapy, and infectious diseases clinical trials.

What does this mean for you?

While Viroclinics-DDL has changed its name, our relationship won’t change. All your existing contracts, agreements, and business relationships will continue as they are and our business structure, team members, contacts, ongoing projects and commitments stay the same. You can continue to rely on us as your trusted partner, and we are excited to continue providing you with the highest level of support.

We value our partnership

We are grateful for your unwavering support and loyalty throughout our journey together. We are genuinely excited about this new chapter in our company’s history and the opportunity to enhance our partnership even further. We look forward to serving you as Cerba Research and delivering continued success to your business.

Want to know more?

We are aware that you might have questions or concerns about this change, and we encourage you to reach out to your dedicated account manager or our customer service team. They will be more than happy to help and answer any questions you may have. Contact Us

To learn more about Cerba Research visit Our Collective Focus  

Your questions answered

1. Where can I find all the VC-DDL services I am used to?

2. How can I contact the former Viroclinics-DDL?

You can contact the former Viroclinics-DDL (now called Cerba Research Netherlands) using the Contact Us form. Please specify the therapeutic area and/or the clinical trials laboratory services you are interested in, so we can make sure you are directed to the right services.

You can also check our locations and reach us by telephone by visiting the following link.

3. Will my contacts change?

All your contacts and teams will stay the same and there are no organizational changes.

4. What has happened to Viroclinics Xplore, Viroclinics Xellerate and the other sub-brands?

These have become part of the Cerba Research organisation and services.

5. Will the change affect how Cerba Research Netherlands operates? 

No, nothing is changing – it is business as usual. There is no impact on current and future studies.

6. Will the legal name also change?

Contact points and official company details such as our legal entity and bank account details will remain unchanged, ensuring a seamless transition for all financial transactions and contractual obligations.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and see how we can help advance your clinical trial

Contact Us